

Immuno-Biological Laboratories, Inc.

WWW.IBL-America.com



How IBL-America is Handling the COVID-19 Challenge

Dear Valued Customer,

We hope that you and your loved ones are healthy during this challenging time.

As COVID-19 continues to impact the globe, we want to ensure that our partners are fully informed on how IBL-America is positioned and prepared to make sure that we continue our business during this difficult period.

All of our efforts are focused on continuously providing our customers with the diagnostic tools they need for their patients or their research studies.

At IBL-America we have been monitoring COVID-19 since the beginning of the year and have been complying with all government-mandated prevention procedures. We have implemented several measures to protect our employees, like special hygiene provisions, extended and flexible working hours and a voluntary work from home policy where appropriate, to keep our company working.

We import products from a number of manufacturers around the world and we try, as much as possible, to maintain a good safety stock of these products including ELISA kits and antibodies.

We also work closely with our import brokers and shipment services to avoid any delays. However, there may be some unavoidable impact on shipment services that are beyond our control. We will do our best to try to resolve any such impact.

As the situation is rapidly changing from day to day we will continue to update all our partners as developments occur.

For the meantime we hope everyone remains safe and should you have any questions or need for support please let us know.

Take care and stay healthy,

A handwritten signature in black ink, appearing to read "Mark Kowal". The signature is fluid and cursive, with a large loop at the end.

Mark Kowal
President and CEO

Immuno-Biological Laboratories, Inc.

8201 Central Avenue NE • Suite P • Minneapolis, MN 55432 USA

Phone: 763-780-2955 • Fax: 763-780-2988 • Toll Free: 888-523-1246 • Email: info@ibl-america.com